ScoreWhy is Krystal Biotech, Inc. ?
1
Poor Management Efficiency with a low ROE of 4.74%
- The company has been able to generate a Return on Equity (avg) of 4.74% signifying low profitability per unit of shareholders funds
2
With a growth in Net Sales of 17.52%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 7 consecutive quarters
- OPERATING CASH FLOW(Y) Highest at USD 200.87 MM
- NET PROFIT(HY) At USD 130.76 MM has Grown at 55.54%
- ROCE(HY) Highest at 18.91%
3
With ROE of 16.80%, it has a very expensive valuation with a 6.00 Price to Book Value
- Over the past year, while the stock has generated a return of 27.08%, its profits have risen by 63.6% ; the PEG ratio of the company is 0.6
4
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
5
Consistent Returns over the last 3 years
- Along with generating 27.08% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Krystal Biotech, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Krystal Biotech, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Krystal Biotech, Inc.
31.12%
0.92
43.27%
S&P 500
13.68%
0.71
19.28%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
229.79%
EBIT Growth (5y)
47.08%
EBIT to Interest (avg)
-32.99
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.63
Sales to Capital Employed (avg)
0.23
Tax Ratio
10.19%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
7.24%
ROE (avg)
4.74%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
36
Industry P/E
Price to Book Value
6.00
EV to EBIT
40.26
EV to EBITDA
38.69
EV to Capital Employed
16.48
EV to Sales
16.67
PEG Ratio
0.57
Dividend Yield
NA
ROCE (Latest)
40.94%
ROE (Latest)
16.80%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Bullish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend15What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 200.87 MM
NET PROFIT(HY)
At USD 130.76 MM has Grown at 55.54%
ROCE(HY)
Highest at 18.91%
RAW MATERIAL COST(Y)
Fallen by 0.48% (YoY
CASH AND EQV(HY)
Highest at USD 1,558.86 MM
NET SALES(Q)
Highest at USD 107.11 MM
OPERATING PROFIT(Q)
Highest at USD 46.03 MM
PRE-TAX PROFIT(Q)
Highest at USD 51.13 MM
-1What is not working for the Company
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.87 times
Here's what is working for Krystal Biotech, Inc.
Operating Cash Flow
Highest at USD 200.87 MM and Grown
In each year in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Profit
At USD 130.76 MM has Grown at 55.54%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
Net Sales
Highest at USD 107.11 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 46.03 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Pre-Tax Profit
Highest at USD 51.13 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Cash and Eqv
Highest at USD 1,558.86 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Raw Material Cost
Fallen by 0.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Depreciation
Highest at USD 1.76 MM
in the last five periodsMOJO Watch
The expenditure on assets done by the company may have gone into operation
Depreciation (USD MM)
Here's what is not working for Krystal Biotech, Inc.
Inventory Turnover Ratio
Lowest at 0.87 times
in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
